Citations

Showing 10 of 108073 citations.

Sensory Input and Motor Responses After Brain Death Diagnosis
Rady, Mohamed Y. , Verheijde, Joseph L.

Mayo Clinic

Journal of Intensive Care Medicine | October 6, 2016 | Volume: 32 | Issue: 2 | Pages: 174-174

10.1177/0885066616672162 | PMID 27758849 Get It

Citrobacter koseri Pneumonia as Initial Presentation of Underlying Pulmonary Adenocarcinoma
Pennington, Kelly M. , Zyl, Martin van , Escalante, Patricio , Van Zyl, Martin

Mayo Clinic

Clinical Medicine Insights: Case Reports | October 6, 2016 | Volume: 9 | Issue: No issue available | Pages: No page available

10.4137/ccrep.s40616 | PMID 27746678 Get It

Citrobacter koseri is a motile, gram-negative rod traditionally known to cause infection in individuals with significant comorbidities and immunocompromised status. While most cases represent nosocomial infections, rarely community-acquired infections have been reported. We present a previously healthy man in his 60s with C. koseri pneumonia who was subsequently found to have underlying pulmonary adenocarcinoma, illustrating the need for further investigation for immunodeficiency and/or intrapulmonary pathology.
Physiology in Perspective: We Learn From Evolutionary/Comparative Physiology
Sieck, Gary C. , Sieck, Gary

Mayo Clinic

Physiology | October 6, 2016 | Volume: 31 | Issue: 6 | Pages: 390-391

10.1152/physiol.00027.2016 | PMID 27708044 Get It

Defining imaging biomarker cut points for brain aging and Alzheimer's disease
Jack, Clifford R. , Wiste, Heather J. , Weigand, Stephen D. , Therneau, Terry M. , Lowe, Val J. , Gunter, Jeffrey L. , Senjem, Matthew L. , Kantarci, Kejal , Mielke, Michelle M. , Roberts, Rosebud O., Vemuri, Prashanthi , Reyes, Denise A., Petersen, Ronald C. , Knopman, David S. , Jones, David T. , Machulda, Mary M. , Jack, Clifford R , Mielke, Michelle M , Vemuri, Prashanthi , Senjem, Matthew L , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | October 5, 2016 | Volume: 13 | Issue: 3 | Pages: 205-216

10.1016/j.jalz.2016.08.005 | PMID 27697430 Get It

Abstract Introduction Our goal was to develop cut points for amyloid positron emission tomography (PET), tau PET, flouro‐deoxyglucose (FDG) PET, and MRI cortical thickness. Methods We examined five methods for determining cut points. Results The reliable worsening method produced a cut point only for amyloid PET. The specificity, sensitivity, and accuracy of cognitively impaired versus young clinically normal (CN) methods labeled the most people abnormal and all gave similar cut points for tau PET, FDG PET, and cortical thickness. Cut points defined using the accuracy of cognitively impaired versus age‐matched CN method labeled fewer people abnormal. Discussion In the future, we will use a single cut point for amyloid PET (standardized uptake value ratio, 1.42; centiloid, 19) based on the reliable worsening cut point method. We will base lenient cut points for tau PET, FDG PET, and cortical thickness on the accuracy of cognitively impaired versus young CN method and base conservative cut points on the accuracy of cognitively impaired versus age‐matched CN method.
The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease
Shujaat, Adil , Thomas, Colleen S. , Rahaghi, Franck , Bajwa, Abubakr A. , Patel, Minal R. , Burger, Charles D.

Mayo Clinic

Pulmonary Circulation | October 5, 2016 | Volume: 7 | Issue: 1 | Pages: 82-88

10.1086/689291 | PMID 28680567 Get It

The primary aim was to explore the safety and tolerability of inhaled treprostinil when used in patients with pulmonary hypertension (PH) with concomitant chronic obstructive pulmonary disease (COPD). Patients with a diagnosis of pre‐capillary PH (defined as pulmonary artery mean pressure of ≥ 25 mmHg and pulmonary artery wedge pressure or left ventricular end diastolic pressure of ≤ 15 mmHg) who were being initiated on inhaled treprostinil and had concomitant COPD (defined as FEV1/FVC ratio ≤ 70% with FEV1 ≥ 40% predicted) were considered for inclusion in this pilot study. Assessments included adverse events, physical exam, World Health Organization (WHO) functional class, 6‐minute walk test (6MWT), modified Borg dyspnea score, and concomitant medication. At baseline and week 16 St. George’s Respiratory Questionnaire (SGRQ), arterial blood gas (ABG), and pulmonary function test (PFT) were assessed. The median age was 65 years (age range, 56–80 years) and five patients (56%) were men. Among the nine patients, a majority had an increase in 6MWT from baseline to week 16 (median change, 19 m). Only three of the nine patients (33%) had an increase in A‐a gradient at week 16 (median change, –7). There was no difference in any of the following: arterial blood gases, WHO functional class, 6MWT results, or SGRQ scores from baseline to week 16. There was a statistically significant decline in several of the PFT measures, including FEV1 (median change, –0.18 L; P = 0.004; median change, –7% of predicted; P = 0.016), FVC (median change, –0.23 L; P = 0.027), and diffusion capacity for carbon monoxide (DLCO) (median change, –5% of predicted; P = 0.023). The small number of patients limits firm conclusions; however, inhaled treprostinil did not seem to adversely impact oxygenation in the majority of the study patients with pre‐capillary PH and COPD. While there may have an adverse impact on some pulmonary function parameters, the clinical significance is unclear.
Experiences of long-term life-limiting conditions among patients and carers: what can we learn from a meta-review of systematic reviews of qualitative studies of chronic heart failure, chronic obstructive pulmonary disease and chronic kidney disease?
May, Carl , Cummings, Amanda , Myall, Michelle , Harvey, J Matthew , Pope, Catherine , Griffiths, Peter , Roderick, Paul , Arber, Mick , Boehmer, Kasey R. , Mair, Frances S , Boehmer, Kasey, Richardson, Alison Mead

Mayo Clinic

BMJ Open | October 5, 2016 | Volume: 6 | Issue: 10 | Pages: e011694

10.1136/bmjopen-2016-011694 | PMID 27707824 Get It

Objectives To summarise and synthesise published qualitative studies to characterise factors that shape patient and caregiver experiences of chronic heart failure (CHF), chronic obstructive pulmonary disease (COPD) and chronic kidney disease (CKD). Design Meta-review of qualitative systematic reviews and metasyntheses. Papers analysed using content analysis. Data sources CINAHL, EMBASE, MEDLINE, PsychINFO, Scopus and Web of Science were searched from January 2000 to April 2015. Eligibility criteria for selecting studies Systematic reviews and qualitative metasyntheses where the participants were patients, caregivers and which described experiences of care for CHF, COPD and CKD in primary and secondary care who were aged ≥18 years. Results Searches identified 5420 articles, 53 of which met inclusion criteria. Reviews showed that patients' and caregivers' help seeking and decision-making were shaped by their degree of structural advantage (socioeconomic status, spatial location, health service quality); their degree of interactional advantage (cognitive advantage, affective state and interaction quality) and their degree of structural resilience (adaptation to adversity, competence in managing care and caregiver response to demands). Conclusions To the best of our knowledge, this is the first synthesis of qualitative systematic reviews in the field. An important outcome of this overview is an emphasis on what patients and caregivers value and on attributes of healthcare systems, relationships and practices that affect the distressing effects and consequences of pathophysiological deterioration in CHF, COPD and CKD. Interventions that seek to empower individual patients may have limited effectiveness for those who are most affected by the combined weight of structural, relational and practical disadvantage identified in this overview. We identify potential targets for interventions that could address these disadvantages. Systematic review registration number PROSPERO CRD42014014547.
Comparison of EX-PRESS Shunt and Trabeculectomy With Mitomycin-C in Congenital and Juvenile Glaucoma
Nash, David L. , Crouch, Eric R. , Crouch, Earl R.

Mayo Clinic

Journal of Glaucoma | October 5, 2016 | Volume: 26 | Issue: 2 | Pages: e58-e63

10.1097/ijg.0000000000000547 | PMID 28146442 Get It

Purpose: To compare efficacy and safety of EX-PRESS mini glaucoma shunt (Alcon) and trabeculectomy with mitomycin-C (MMC) in the management of pediatric glaucoma. Methods: The authors retrospectively reviewed patients from a single pediatric ophthalmology practice with either congenital or juvenile glaucoma who underwent surgical treatment with either trabeculectomy or EX-PRESS shunt insertion with MMC. Postoperative intraocular pressure at 6, 18, and 36 months, medication requirements, visual acuities, postoperative interventions, complications, and noncompliance with medications or follow-up was reviewed. Results: A total of 42 cases of glaucoma with either trabeculectomy or EX-PRESS shunt were identified for review (n trabeculectomy=25, n EX-PRESS=17). At 6 months, 62.5% of trabeculectomies and 94.1% of EX-PRESS shunts met criteria for success (P=0.0281). At 18 months, 38.1% of trabeculectomies and 81.3% of EX-PRESS shunts met criteria for success (P=0.0178). At 36 months, trabeculectomies had a success rate of 33.3% versus 66.7% for EX-PRESS shunts (P=0.321). The average decrease in medications postoperatively was 0.375 and 1.63 for trabeculectomy and EX-PRESS shunt, respectively (P=0.06). Preoperative visual acuities compared with postoperative best-corrected visual acuities before additional surgery demonstrated a slight average worsening of 0.11 logMAR in trabeculectomy patients and an average improvement of 0.56 logMAR in EX-PRESS shunt patients (P=0.0037). Conclusions: In this review, patients with pediatric glaucoma managed with EX-PRESS shunt with MMC compared with trabeculectomy with MMC appear to have better intraocular pressure control, better visual acuities, and fewer complications and reoperations.
A Comparison of Mohs Micrographic Surgery and Wide Local Excision for Treatment of Dermatofibrosarcoma Protuberans With Long-Term Follow-up: The Mayo Clinic Experience
Lowe, Garrett C., Onajin, Oluwakemi , Baum, Christian L. , Otley, Clark C. , Arpey, Christopher J., Roenigk, Randall K., Brewer, Jerry D.

Mayo Clinic

Dermatologic Surgery | October 5, 2016 | Volume: 43 | Issue: 1 | Pages: 98-106

10.1097/dss.0000000000000910 | PMID 27749444 Get It

BACKGROUND Dermatofibrosarcoma protuberans (DFSP) is a soft tissue tumor with slow infiltrative growth and local recurrence if inadequately excised. OBJECTIVE To compare long-term outcomes after Mohs micrographic surgery (MMS) and wide local excision (WLE). MATERIALS AND METHODS Records of patients with DFSP surgically treated with WLE or MMS from January 1955 through March 2012 were retrospectively reviewed. RESULTS Mean follow-up for patients treated with MMS (n = 67) and WLE (n = 91) was 4.8 and 5.7 years, respectively. Twenty-eight patients (30.8%) with WLE had recurrence (mean, 4.4 years), whereas only 2 (3.0%) with MMS had recurrence (1.0 and 2.6 years). Recurrence-free survival rates at 1, 5, 10, and 15 years were significantly higher with MMS (p < .001). Mean preoperative lesion sizes were similar (5–6 cm) between the 2 groups, whereas mean (standard deviation) postoperative defect sizes were 10.7 (4.3) cm and 8.8 (5.5) cm for WLE and MMS, respectively (p = .004). Primary closure was used for 73% of MMS cases, whereas WLE more commonly used flaps, grafts, or other closures (52%). Two Mohs layers typically were required for margin control. CONCLUSION Surgical excision with meticulous histologic evaluation of all surgical margins is needed for DFSP treatment to achieve long-term high cure rates and low morbidity.
Response to the letter by Sugiyama and Oda
Mughal, M.Z., Thacher, Tom D. , Kiely, Máiréad , Munns, Craig F. , Högler, Wolfgang , SPECKER, BONNY L , Shaw, Nicola , Thacher, Thomas D

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | October 5, 2016 | Volume: 101 | Issue: 10 | Pages: L97-L98

10.1210/jc.2016-3059 | PMID 27702314 Get It

Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
Kumar, Shaji , LaPlant, Betsy, Reeder, Craig B. , Halvorson, Alese E. , Bergsagel, P. Leif , Thompson, Melanie , Crawley, Jamie , Kapoor, Prashant , Stewart, Keith, Hayman, Suzanne R. , Hwa, Yi L. , Dingli, David , Lin, Yi , Rivera, Candido E., Lacy, Martha Q. , Nahi, Hareth , Bergsagel, P. Leif , Kumar, Shaji K , LaPlant, Betsy R, Mıkhael, Joseph , Roy, Vivek , Buadi, Francis K. , Gertz, Morie A. , Dispenzieri, Angela , Gonsalves, Wilson I. , Witzig, Thomas E. , Ailawadhi, Sikander , Go, Ronald S. , Rajkumar, S. Vincent , Dingli, David , Lin, Yi , Nahi, Hareth

Mayo Clinic

Blood | October 4, 2016 | Volume: 128 | Issue: 20 | Pages: 2415-2422

10.1182/blood-2016-05-717769 | PMID 27702799 Get It

Key Points The combination of ixazomib and dexamethasone has clinical activity in patients with relapsed and or refractory multiple myeloma. Higher dose of ixazomib leads to improved response rates but with higher rates of treatment related adverse events.